Seagen Digs Deep For Lava’s Bispecific Antibody

 
• By Alaric DeArment
  
Seagen and Lava signed a licensing deal for Lava's preclinical bispecific antibody candidate, LAVA-1223 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business